ME Therapeutics Holdings Valuation
Is Q9T undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of Q9T when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate Q9T's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate Q9T's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for Q9T?
Key metric: As Q9T is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is Q9T's PB Ratio? | |
|---|---|
| PB Ratio | n/a |
| Book | €0 |
| Market Cap | €56.83m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does Q9T's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.3x | ||
2INV 2invest | 1x | n/a | €63.8m |
VSC 4SC | 44x | n/a | €48.2m |
HPHA Heidelberg Pharma | 2.9x | -33.0% | €103.9m |
MDG1 Medigene | 1.2x | -4.1% | €22.6m |
Q9T ME Therapeutics Holdings | n/a | n/a | €82.7m |
Price-To-Book vs Peers: Insufficient data to calculate Q9T's Price-To-Book Ratio vs. peers for valuation analysis.
Price to Book Ratio vs Industry
How does Q9T's PB Ratio compare vs other companies in the DE Biotechs Industry?
| 3 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: Insufficient data to calculate Q9T's Price-To-Book Ratio vs. industry for valuation analysis.
Price to Book Ratio vs Fair Ratio
What is Q9T's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate Q9T's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.29
7D
-1.8%
1Y
0.2%